"Johnson & Johnson has hiked its dividend for 63 consecutive years, and stands poised to deliver its 64th annual increase when it reports first-quarter 2026 earnings before the market opens on April 14. That track record isn't luck - it's the result of disciplined capital allocation across its diversified portfolio of medicines, medical devices, and consumer health products."
"Last year, Johnson & Johnson raised its quarterly payout from $1.24 to $1.30 per share, a near-5% increase. The stock now yields 2.14% at an annualized $5.20 per share. Over the past decade, it has delivered 5% compounded annual growth."
"Johnson & Johnson's full-year 2025 results showed reported sales of $94.2 billion, up 6% from 2024. Operational growth hit 5.3%, even after accounting for the loss of exclusivity on Stelara."
Johnson & Johnson has raised its dividend for 63 consecutive years, demonstrating a strong commitment to shareholder returns. The company is expected to announce its 64th increase in April 2026. With a recent quarterly payout increase to $1.30 per share and a yield of 2.14%, Johnson & Johnson showcases a solid financial foundation. The company reported $94.2 billion in sales for 2025, with significant growth in its Innovative Medicine segment. Adjusted earnings reached $10.79 per share, reflecting a robust operational performance.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]